Look up one drug

Zarontin · DIN 00023485 Manufacturer: Searchlight Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-10-11 · brand ZARONTIN SYRUP · ATC N03AD01 ETHOSUXIMIDE · form Syrup · route Oral · ingredients ETHOSUXIMIDE 250 MG/5ML · company Searchlight pharma inc · schedule Prescription

DIN 00023485: Zarontin Raw flags: sec3=Y Item: 281200009; group id 429; item number 1069; lccId None; manufacturer id SLP Source form: O/L; strength: 50mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0740; ministry $0.0740 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00023485 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=731

Shortage status: resolved shortage (ended 2022-05-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00023485

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mar-Ethosuximide · DIN 02545772 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2024-12-30 Health Canada: Marketed since 2024-06-19 · brand MAR-ETHOSUXIMIDE · ATC N03AD01 ETHOSUXIMIDE · form Capsule · route Oral · ingredients ETHOSUXIMIDE 250 MG · company Marcan pharmaceuticals inc · schedule Prescription

DIN 02545772: Mar-Ethosuximide Raw flags: sec3=Y Item: 281200008; group id 429; item number 1068; lccId None; manufacturer id MAR Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.2628; ministry $0.2628 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545772 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103451

Interchangeable products

Odan-Ethosuximide · DIN 02547171 · $0.2628 Zarontin · DIN 00022799 · $0.2628

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545772

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Odan-Ethosuximide · DIN 02547171 Manufacturer: Odan Laboratories Ltd.; listing date 2024-12-30 Health Canada: Marketed since 2024-06-25 · brand ODAN-ETHOSUXIMIDE · ATC N03AD01 ETHOSUXIMIDE · form Capsule · route Oral · ingredients ETHOSUXIMIDE 250 MG · company Odan laboratoriesltd · schedule Prescription

DIN 02547171: Odan-Ethosuximide Raw flags: sec3=Y Item: 281200008; group id 429; item number 1068; lccId None; manufacturer id ODN Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.2628; ministry $0.2628 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547171 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103582

Interchangeable products

Mar-Ethosuximide · DIN 02545772 · $0.2628 Zarontin · DIN 00022799 · $0.2628

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547171

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zarontin · DIN 00022799 Manufacturer: Searchlight Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-10-11 · brand ZARONTIN · ATC N03AD01 ETHOSUXIMIDE · form Capsule · route Oral · ingredients ETHOSUXIMIDE 250 MG · company Searchlight pharma inc · schedule Prescription

DIN 00022799: Zarontin Raw flags: sec3=Y Item: 281200008; group id 429; item number 1068; lccId None; manufacturer id SLP Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.5255; ministry $0.2628 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00022799 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=771

Interchangeable products

Mar-Ethosuximide · DIN 02545772 · $0.2628 Odan-Ethosuximide · DIN 02547171 · $0.2628

Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00022799

Shortage record checked 2026-09-13T08:10:21.292534+00:00